Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million dollar grant from the NIH to advance research in organ transplantation and antibody mediated rejection.
The U.S. Department of Health and Human Services, through the Centers for Medicare and Medicaid Services, has released final guidance outlining the process for the second cycle of negotiations under the Medicare Drug Price Negotiation Program.
The Centers for Medicare and Medicaid Services issued a final rule on its 2025 home health prospective payment system, which updates Medicare payment policies and rates for home health agencies.
FluMist, the first influenza nasal spray vaccine that can be self-administered, has been approved by the U.S. Food and Drug Administration (FDA).
A rule has been proposed by the U.S. Department of Health and Human Services to advance health equity and support whole-person care.
According to randomized controlled trials, repeat intravenous immune globulin (IVIG) dosing and plasma exchange (PLEX) followed by IVIG (combination therapy) have no additional therapeutic benefit in Guillain-Barré syndrome (GBS) nonresponders. Furthermore, the delineation between GBS and acute onset chronic inflammatory demyelinating polyneuropathy (A-CIDP) can be particularly challenging and carries therapeutic implications.
According to a recent study published in JAMA Network Open, the estimated effectiveness of at least one dose of the influenza vaccine against emergency department visits or hospitalization was over 50 percent across disease severity levels among nearly 16,000 U.S. children during five respiratory illness seasons.
Remestemcel-L, a new treatment for children ages 2 months and older with steroid-refractory acute graft-versus-host disease, has been approved by the U.S. Food and Drug Administration.
Celltrion has received U.S. Food and Drug Administration approval for its autoimmune disease treatment drug Steqeyma, a biosimilar of Johnson & Johnson’s Stelara (ustekinumab).
The U.S. Food and Drug Administration (FDA) has granted fast track designation for its lead clinical-stage program, IMM-1-104, as a treatment for patients with unresectable or metastatic NRAS-mutant melanoma who have progressed on or are intolerant to PD-1/PD-L1-based immune checkpoint inhibitors.
Scientists from RMIT University and the Doherty Institute in Australia have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.
